
Sarepta Therapeutics (SRPT) Stock Forecast & Price Target
Sarepta Therapeutics (SRPT) Analyst Ratings
Bulls say
Sarepta Therapeutics Inc. has reported a consistent number of start forms, with management expressing optimism for an inflection point in growth that could propel annual sales beyond the $500 million mark. The preliminary fourth-quarter 2025 net revenue of $259.2 million represents a 9% increase from the previous quarter, reflecting stable adoption of the company's products, while the revenue from its ELEVIDYS treatment reached $110.4 million, suggesting a significant potential run-rate of approximately $442 million annually. Positive initial data from ongoing Phase 1/2 programs in FSHD and DM1 could present additional growth opportunities, bolstered by favorable feedback from key opinion leaders regarding ELEVIDYS’s risk/benefit profile for both ambulatory and non-ambulatory patients.
Bears say
Sarepta Therapeutics Inc. faces a challenging financial outlook due to lower-than-expected preliminary net revenue for its product Elevidys in the fourth quarter of 2025, which fell short of consensus estimates. The company has highlighted concerns regarding revenue volatility, as the postponement of treatment for just a few patients significantly impacts quarterly results, indicating fragility in product demand. Furthermore, ongoing questions about Elevidys's efficacy and safety profile, combined with the emergence of competitive therapies that may provide better benefit-risk balances, contribute to a negative sentiment around the company's future financial stability.
This aggregate rating is based on analysts' research of Sarepta Therapeutics and is not a guaranteed prediction by Public.com or investment advice.
Sarepta Therapeutics (SRPT) Analyst Forecast & Price Prediction
Start investing in Sarepta Therapeutics (SRPT)
Order type
Buy in
Order amount
Est. shares
0 shares